Ksenija Nesic

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (13)

• Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial
  Chee Khoon Lee, Apriliana E. R. Kartikasari, Nirashaa T. Bound +32 more
  Nature Communications 2025 DOI: 10.1038/s41467-025-64130-6
  +Save
• Demethylating agents drive PARP inhibitor resistance in ovarian carcinomas with BRCA1 gene silencing
  Ksenija Nesic, Franziska Geissler, Lijun Xu

  +19 more

  • Elizabeth L. Kyran
  • Sally Beard
  • Cassandra J. Vandenberg
  • Brett Liddell
  • Sam W.Z. Olechnowicz
  • +14 more
  2025 DOI: 10.1101/2025.04.07.647418
  +Save
• Farletuzumab ecteribulin and MORAb‐109, folate receptor alpha and mesothelin targeting antibody–drug conjugates, show activity in poor prognosis gynaecological cancer models
  Clinical and Translational Medicine 2025 DOI: 10.1002/ctm2.70274
  +Save
• The role of aberrant DNA methylation in cancer initiation and clinical impacts
  Therapeutic Advances in Medical Oncology 2024 DOI: 10.1177/17588359231220511
  +Save
• Targeting homologous recombination deficiency in uterine leiomyosarcoma
  Journal of Experimental & Clinical Cancer Research 2023 DOI: 10.1186/s13046-023-02687-0
  +Save
• BRCA1secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
  2023 DOI: 10.1101/2023.03.20.23287465
  +Save
• Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma
  Ksenija Nesic, Olga Kondrashova, Rachel M. Hurley +28 more
  Cancer Research 2021 DOI: 10.1158/0008-5472.can-21-0774
  +Save
• Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance
  NAR Cancer 2021 DOI: 10.1093/narcan/zcab028
  +Save
• Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma
  bioRxiv 2020 DOI: 10.1101/2020.12.10.419176
  +Save
• Characterization of a RAD51C-silenced high grade serous ovarian cancer model during PARP inhibitor resistance development
  bioRxiv 2020 DOI: 10.1101/2020.12.25.419978
  +Save
• Diverse mechanisms of PARP inhibitor resistance in ovarian cancer
  Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2019 DOI: 10.1016/j.bbcan.2019.08.002
  +Save
• Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
  Olga Kondrashova, Monique D. Topp, Ksenija Nesic +97 more
  Nature communications 2018 DOI: 10.1038/s41467-018-05564-z
  +Save
• Targeting DNA repair: the genome as a potential biomarker.
  The Journal of pathology 2018 DOI: 10.1002/path.5025
  +Save